Stivarga Regulatory Post-Marketing Surveillance Study in Korea
Latest Information Update: 14 Jun 2019
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer; Gastrointestinal stromal tumours
- Focus Adverse reactions
- Acronyms StivargaPMS
- Sponsors Bayer
- 11 Jun 2019 Status changed from active, no longer recruiting to completed.
- 04 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 19 Oct 2018 Planned number of patients changed from 3750 to 300.